ENDPOINTS

Eli Lilly to buy gene editing biotech Verve Therapeutics for up to $1.3B

It appears that Eli Lilly couldn’t wait to get its hands on Verve Therapeutics’ PCSK9 program. Lilly said Tuesday that it will buy the gene editing biotech for about $1 billion at $10.50 per share ...

Jun 17, 2025 - 12:20
 0
Eli Lilly to buy gene editing biotech Verve Therapeutics for up to $1.3B
It appears that Eli Lilly couldn’t wait to get its hands on Verve Therapeutics’ PCSK9 program. Lilly said Tuesday that it will buy the gene editing biotech for about $1 billion at $10.50 per share ...
Read More

Tags:

Previous Article

Old-growth forests are at risk. Here’s why they matter so much for people and th...

Next Article

PhD students face high risk of sexual harassment — can universities stop perpetr...

Related Posts

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Novo turns to Septerna for oral obesity medicines in de...

May 14, 2025  0

NextCure inks ADC deal with Simcere Zaiming

NextCure inks ADC deal with Simcere Zaiming

Jun 16, 2025  0

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio

Pfizer joins PD-1xVEGF race with $1.25B upfront to Chin...

May 20, 2025  0